XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Operating activities    
Net loss $ (14,412) $ (31,712)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Amortization expense for Nucynta asset acquisition 7,376 61,933
Depreciation and amortization, excluding Nucynta asset acquisition 355 578
Stock-based compensation expense 8,425 6,254
Non-cash lease expense 229  
Non-cash interest expense for Nucynta asset acquisition   11,471
Changes in operating assets and liabilities:    
Accounts receivable (3,333) (58,411)
Inventory (2,136) (508)
Prepaid expenses and other assets 509 (608)
Accounts payable (1,209) 13,008
Accrued expenses (3,285) 13,917
Accrued rebates, returns and discounts 13,481 69,346
Operating lease asset and liabilities 734  
Other long-term liabilities (676)  
Net cash provided by operating activities 6,058 85,268
Investing activities    
Upfront cash paid for Nucynta asset acquisition   (18,877)
Purchases of property and equipment (4,198) (987)
Net cash used in investing activities (4,198) (19,864)
Financing activities    
Cash paid for common stock offerings costs   (30)
Proceeds from issuances of common stock from employee stock purchase plans 444 510
Proceeds from term loan amendment, net of repayment of amended term loan   10,020
Repayment of asset acquisition obligations   (64,500)
Proceeds from the exercise of stock options 299 3,905
Payments made for employee restricted stock tax withholdings (523) (356)
Net cash provided by (used in) financing activities 220 (50,451)
Net increase in cash, cash equivalents and restricted cash 2,080 14,953
Cash, cash equivalents and restricted cash at beginning of period 146,633 118,794
Cash, and cash equivalents and restricted cash at end of period 148,713 133,747
Supplemental disclosure of cash flow information    
Cash paid for offering costs   30
Cash paid for interest 362 242
Supplemental disclosure of non-cash activities    
Offering costs in accrued expenses   25
Receivable from stock option exercises in other current assets 5  
Acquisition of property and equipment in accounts payable and accrued expenses 512 1,184
Operating lease assets assumed 9,957  
Operating lease liabilities assumed $ 10,691  
Liabilities assumed from Nucynta asset acquisition included in accrued rebates, returns and discounts   22,406
Liabilities assumed from Nucynta asset acquisition included as a reduction to accounts receivable   $ 254